Takeda’s Entyvio receives FDA approval for subcutaneous administration

Takeda has received approval from the US Food and Drug Administration (FDA) for subcutaneous (SC) administration of Entyvio (vedolizumab) to treat moderately to severely active ulcerative colitis (UC) in adults.